RESULTS Forty consecutive patients (male 78%, mean age 59.9 AE 8.3, diabetics 30%) with CTO treated with BVS were enrolled. A total of 63 BVS were implanted with the average number of 1.6 per patient, and the scaffold length of 42.4 AE 21.5 mm. Mean J-CTO score was 1.6. Antegrade approach was used in 38 patients (95%), and retrograde, after failed antegrade, in the remaining two (5%). High pressure postdilatation was performed in 38 patients. Procedural success was achieved in all patients with no device-related complications. IVUS was used in two, whereas OCT in ten patients. On QCA the mean inscaffold final MLD was 2.13 AE 0.31 mm and residual stenosis 13.90 AE 7.59%. In OCT analysis, performed in 10 patients, the minimal inscaffold luminal diameter was 2.65 AE 0.45 mm, minimal luminal area 6.15 AE 0.20 mm2, and lumen area stenosis 17.7 AE 11.1%. At follow-up (median time 434 days), there were no deaths, one patient experienced subacute and late scaffold thrombosis (ST), another one developed symptomatic in-scaffold focal restenosis treated with repeat PCI. At control angiography, performed at the median time of 264 days in 23 patients (58%), the mean in-scaffold diameter stenosis was 22.42 AE 12.74, and the mean late lumen loss was 0.24 AE 0.55 mm. No more restenosis or vessel reocclusion was found.
BACKGROUND The bioresorbable vascular scaffold (BVS) is a new therapy that provides transient vessel support with drug delivery capability, potentially without the limitations of permanent metallic implants. It can be an alternative option to currently used drug eluting stents (DES) for percutaneous coronary intervention (PCI) of ischemic coronary artery disease (CAD). We aimed to compare the non-inferiority of BVS use to DES.
METHODS We searched Pub Med and Cochrane through June 2015 for all randomized clinical trials (RCTs) that directly compared BVS and DES for ischemic CAD. Primary outcome was target vessel revascularization (TVR). Secondary outcomes included cardiac death, acute myocardial infarction, and definite or probable stent thrombosis (ST). We used Fixed or Random Effect analysis using the Cochrane Handbook of Systematic Reviews and RevMan 5.2 for statistical analysis.
RESULTS Out of 257 articles, four randomized trial studies were included. The pooled data provided 3873 patients; 2024 treated with BVS and 1849 with Everolimus drug-eluting stent. Mean follow up was 12 months. There was a trend towards lower TVR in BVS group compared to Everolimus group (2.7% vs. 4.5%, p¼0.1) ( Figure 1 ). There was no difference in cardiac death (0.7 % vs. 0.7%, p¼0.8), AMI (3.4% vs. 3.4%, p¼0.9) and ST (0.6% vs. 0.7%, p¼0.9) between the two groups ( Figure 2 ). CONCLUSIONS Our analysis showed similar outcomes between two treatment modalities. This suggests that BVS might not be inferior to DES for PCI of ischemic CAD. Further randomized trials should be pursued to confirm those findings. BACKGROUND Bioresorbable scaffolds (BRS) are an attractive option for the percutaneous treatment of coronary artery disease due to the potential advantages associated with its complete absorption within 3-4 years of implantation. However, due the current design of BRS with thicker struts compared to contemporary metallic stents, some concern remains that this property may be associated with adverse events including thrombosis and restenosis when using small BRS.
METHODS Among 350 consecutive lesions treated with Absorb BRS during May 2012 -Apr 2015 at 2 high volume centers in Milan, 116 lesions were treated using 2.5 mm BRS (small BRS group) and 234 lesions were treated with BRS >2.5 mm BRS (large BRS group). Outcomes including target lesion revascularization (TLR) per lesion and definite stent thrombosis were investigated.
RESULTS
The number of BRS was higher and the total BRS length was longer in the small BRS group when compared to the large BRS group (1.7 AE 0.8 vs 1.4 AE 0.6; p<0.001, and 42.3 AE 22.6 mm vs 30.7 AE 15.0mm; p<0.001, respectively). As expected, the post procedural minimum lumen diameter was significantly smaller in the small BRS group (2.36 AE 0.43mm vs 2.82 AE 0.44mm; p<0.001). TLR-free rate (median follow-up; 441days, interquartile range; 150-503 days) did not differ between the two groups (p¼0.59). One-year TLR free rate was 95.7 AE 2.1% in the small BRS group and 92.5 AE 2.1% in the large BRS group. There were no differences between groups with regards to definite stent thrombosis with was 1 late thrombosis in the small BRS group and 1 acute thrombosis in the large BRS group.
CONCLUSIONS Percutaneous coronary intervention using small BRS was associated with comparable outcomes when compared to larger BRS with no observed increase in adverse events. METHODS Twenty Adult New Zeeland white rabbits were anaesthetized and a long 6 Fr arterial sheath was placed in the carotid artery extending to the distal aorta. Heparin was administered. Bifurcation stenting procedures of the aorta-iliac bifurcation (70 angle) were performed with 3.0x28 mm BVS using the following techniques: mainvessel (MV) stenting with ballooning of side branch (SB) through the BVS struts (Provisional stenting, n¼5), T-and protrusion (TAP, n¼5), modified T (n¼5) and culotte (n¼5) stenting. Proximal optimization technique with 3.5 mm non-compliant (NC) balloons at 16 atm and mini-kissing balloon post-dilatation with 3.0 NC balloons at 5 atm were performed in all procedures. Angiography, optical coherence tomography (OCT) and post-procedural micro-computed tomography (micro-CT) were performed.
In all procedures angiographic results were excellent with no evidence of dissection or SB compromise. Re-crossing through BVS struts with guidewires and balloons þ/second BVS (TAP þ culotte procedures) was smooth. Provisional stenting optimally opened the SB ostium without deforming the BVS. On OCT there was no malapposition and micro-CT revealed good SB aperture and a single connector fracture was present in the MV in 1 of the 5 cases. Modified T stenting (SB stented first, n¼5) and TAP stenting (MV stented first, n¼5) resulted in complete coverage of the SB ostium and carina. In both techniques no significant malapposition was present. On Micro-CT, no strut fractures were present following modified T stenting, whilst in 3 out of 5 TAP procedures single strut fractures were noted, these did not cause luminal compromise. Culotte stenting (n¼5) resulted in complete coverage of the bifurcation with an extensive proximal segment of double-layered scaffold struts. In 3 of the 5 culotte procedures, OCT revealed significant circumferential malapposition at the level of the bifurcation. On micro-CT there was distortion of MV and SB scaffolds at the level of the bifurcation with single strut fractures present in all 5 cases. These fractures did not cause luminal compromise.
CONCLUSIONS In this non-diseased in-vivo aorta-iliac bifurcation model, it was feasible to perform complex bifurcation stenting using Absorb BVS with excellent angiographic results. Provisional stenting with additional TAP stenting seems a reasonable standard approach for most bifurcation lesions. When a 2-stent technique is planned from the outset, modified T-stenting was the most promising with no evidence of significant malapposition or scaffold disruption on OCT and micro-CT, respectively. Finally, culotte stenting frequently caused significant circumferential malapposition, scaffold distortion and strut fractures, the clinical impact of which is unknown. BACKGROUND Multiple studies have proven safety and feasibility of the BVS bioresorbable scaffold. However, most of these studies were restricted by rather non-complex lesions or short follow-up.
METHODS This is an investigator initiated, prospective, mono-center, single-arm study. Inclusion criteria were patients presenting with NSTEMI, stable, unstable angina, or silent ischemia caused by a de novo stenotic lesion in a native previous untreated coronary artery. Lesions with a Dmax (proximal and distal mean lumen diameter) within the upper limit of 3.8 mm and the lower limit of 2.0 mm by online QCA were obligatory. Exclusion criteria were patients with a history of CABG, presentation with cardiogenic shock, bifurcation lesions requiring kissing balloon post-dilatation, STEMI patients requiring immediate stent implantation, allergies or contra-indications to antiplatelet therapy, female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding, expected survival of less than one year. Procedural outcomes and clinical outcomes were assessed.
RESULTS From September 2012 to January 2015, 250 patients with 335 lesions were enrolled in this study. A total of 445 BVS were placed with a mean number of implanted scaffolds/ patient of 1.37. Predilatation was performed in 89.8%. Predilatation balloon: artery ratio was 1.05AE0.23. Post-dilatation was performed in 54.3%. In 14.5% baseline imaging using IVUS was used; OCT in 24.9%. Bifurcation was present in 21.4%, calcification in 42.2% and total occlusions in 4.2%. In 38.0% there were AHA classification type B2/ C lesions. Mean lesion length was 22.10AE13.90 mm. Pre-procedural reference vessel diameter (RVD) was 2.42AE0.74mm, minimal lumen diameter (MLD) 0.91AE0.45mm and percentage diameter stenosis (%DS) 59.13AE 0.72. Post-procedural QCA characteristics were as followed: RVD 2.77AE0.46 mm, MLD 2.30AE0.42 mm and %DS 16.90AE9.04. Median follow-up period was 559 days (interquartile range [IQR], 371-733 days). Up to 12 months three patients died (all cardiac death) with a Kaplan Meier estimate of 1.4% at one year. Rate of all myocardial infarction (MI) was 4.1%, definite scaffold thrombosis (ST) 1.4%, target lesion revascularization (TLR) and target vessel revascularization (TVR) were 3.7%. Non-target vessel revascularization (non-TVR) was 3.8%. Major cardiac adverse events (MACE, a composite endpoint of cardiac death, TLR and all MI) at one year was 5.5%.
CONCLUSIONS Long-term results in a mixed group of patients imply that BVS usage is associated with favorable clinical outcomes. 
